InvestorIdeas.com and China-AsiaStocks.com, its investor and industry portal focused on the China-Asia sector, updates its growing stock directory with new public company listings as investors witness the China IPO frenzy and seek investment opportunities in the sector. From Shanghai’s listing of oil and gas conglomerate, PetroChina- China's largest domestic IPO, to the recent Alibaba.com IPO on the Hong Kong stock exchange, the market can’t fill the growing appetite for China related listings.
According to a recent report by Ernst & Young, companies in mainland China and Hong Kong raised $14.3 billion in the third quarter and the number of company listings in Hong Kong and mainland China hit new records. Philip Leung commented in their release “The record number of IPO’s shows that companies were quick to react to keen investor interest in equities“.
Outside of American Depositary Shares (ADS), investors can also invest in the China play in the micro cap markets. After Market Support, LLC, a wholly owned subsidiary of Keating Investments, is a financial marketing firm specializing in creating liquidity for publicly traded stocks and has worked with multiple clients that have gone public through reverse mergers (a method of going public increasingly replacing IPOs for micro cap issuers). Keating has an office and division in Shanghai (keatingasia.com) According to Justin Davis of After Market Support, LLC., currently working with Benda Pharmaceutical, Inc., (OTCBB: BPMA), smaller listed companies can provide investors the opportunity to get in on the ground floor of China’s dramatic growth story. Justin does advise investors to complete their own due diligence and review SEC filings prior to investing.
“To become a Keating reverse merger client like Benda Pharmaceutical, a Chinese company must first pass muster through a rigorous and multi-layered due diligence process. Keating begins with an overall analysis of the industry, market opportunity, the company’s relative competitiveness and growth potential. If a company clears immediate hurdles, Keating then drills deeper into business, financial and legal due diligence, conducting multiple site visits and contracting independent, professionally-executed background checks. Finally, each company must have in place a management team that understands the business of being a U.S. public company. Many firms do not stand up to this level of scrutiny. Those that remain resemble Benda – already profitable, Benda has tremendous growth potential via Gendicine®, the first gene therapy drug for the treatment of cancer on the market, anywhere in the world.“
Benda Pharmaceutical (OTCBB: BPMA) is building its presence within the fast growing Chinese market and beyond, forecasting that Gendicine® will generate $16 million in revenue in 2008, up from estimates of $6.2 million for 2007. In total, the Company anticipates revenues to reach $25.1 million in 2007 and progressing upwards to $56.7 million in 2008.
Yahoo!s (NASDAQ: YHOO) US$1 billion investment (40% interest) in Alibaba’s business-to-business trading portal, represents another alternative for U.S. investors looking to participate in and own shares in companies doing business in China.
Some notable recent and pending China listing market debuts include- Longtop's (NYSE:LFT) American Depositary Shares, posting significant gains its first day of trading Longtop, provides information technologies services to China's financial services sector.
Also making headlines- China National Heavy Duty Truck Co, a heavy truck maker, in a Hong Kong IPO and Giant Interactive Group Inc ADSs (NYSE: GA), an online game developer. In the pipeline is AirMedia, planning to list its ADSs on NASDAQ, trading symbol AMCN.
FUQI International, Inc. (NASDAQ: FUQI) recent IPO at $9.00 has already had a range of $6.50 - $11.75 and is currently down from its IPO debut. FUQI International, Inc. designs high quality precious metal jewelry in China.
Benda Pharmaceutical Inc. is a Showcase Company on Investor Ideas. Compensation is disclosed in disclaimer.
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, Middle East and Australia.
InvestorIdeas.com Disclaimer: Our sites do not make recommendations, but offer information portals .Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Benda Pharmaceutical, Inc. (OTCBB: BPMA) $4000USD per month.
Source: China-AsiaStocks.com, Benda Pharmaceutical, Inc.